David H. Crean
Chief Business OfficerDr. David H. Crean, Ph.D., MBA, is Venture Partner of VU Venture Partners. He focuses on Healthcare North America, Europe, & LatAm. Dr. Crean had been served as Member of Advisory Board of Origami Therapeutics, Inc until 2023. He serves as an Investment Partner at Suncoast Ventures Management, LLC. Previously, he served as a Venture Partner of Suncoast Ventures Management, LLC. He also serves as Investment Partner at Mesa Verde Venture Partners. Dr. Crean has been Chief Business Officer at MediciNova, Inc. since May 2021. Dr. Crean had been Lead Independent Director of Histogen, Inc. since November 2021 until March 10, 2023 and serves as its Independent Director. Dr. Crean had been the Independent Chairman of Histogen, Inc. since May 26, 2020, until November 2021 and had been its Director since March 2018 until May 2020. Dr. Crean is President and CEO of Coast BioVentures LLC. In parallel, he is a managing Partner with Cardiff Advisory LLC. He serves on the Board of Directors for the California Life Sciences Association. He is a Member of Corporate Directors Forum and BIOCOM. Dr. Crean is also a contributing author for PharmaBoardroom.com and Forbes.com through his work with Forbes Los Angeles Business Council. Dr. Crean had been the Chief Executive Officer and Director of Talapo Therapeutics since March 2018 until May 2020. He served as Managing Director at Objective Capital Partners, LLC since September 2015 until 2020. Dr. Crean led Objective Capital Partners life science investment banking transactions. He serves in a senior advisory capacity at Objective Capital Partners. From 2013 to 2015, he was the President and Chief Executive Officer of the Boys & Girls. He is Managing General Partner of Coast BioVentures LLC. He led the healthcare and life sciences practice at Objective. Over the years at the firm, he built a high-quality team from the ground up and executed more than 10 transactions in the healthcare sector. He currently serves on the board of directors for Paracrine, Inc., Almon Therapeutics. He also provided strategic input and review on over 750 company and technology opportunities over this time period and acted as strategic financial advisor to over 50 clients enabling them to seek their short- and long-term goals. Prior to investment banking and private equity, he was in corporate business development within strategic pharmaceutical companies, most notably at Allergan, an Abbvie Company, and Aqua Pharmaceuticals. At Allergan, he was charged with driving all negotiation and deal execution for technology, product, and company acquisitions and divestitures. He drove geographically dispersed transactions including transactions involving brands such as BOTOX, Restasis, Tazarotene, Juvederm, Aczone, and Alphagan. He serves as Chair of BIOCOM Capital Development. He served as Vice President of Corporate Development at Aqua Pharmaceuticals, LLC. In this role, he was responsible for all Aqua's acquisition, licensing and corporate initiatives. He joined Aqua following a Senior Director for Business Development position with Allergan, Inc., where he worked primarily in new business generation and transaction execution in support of growing many of Allergan's business units including topical facial aesthetics, therapeutic skin care and movement-related neurological disorders. Prior to his role in business development, he served as a Director of Project and Portfolio Management, where he was responsible for leading critical drug development programs. He was previously the Chairman of the Board for Phoenix Molecular Designs. He serves as an Independent Board Member for Andrew Technologies, LLC. He serves as a strategic business advisor for several life science companies. Dr. Crean has life sciences R&D and corporate development transactional experience in the pharmaceutical industry where he was responsible for leading mergers, acquisitions, licensing and collaborations, and establishing corporate strategy. He holds FINRA Series 79 and Series 63 licenses and is a Registered Representative of BA Securities LLC, Member FINRA SIPC. Dr. Crean serves as a strategic business advisor for several life science companies. Dr. Crean has MBA in Finance from Pepperdine University Graziadio School of Management, Ph.D. in biophysics from State University of New York at Buffalo – School of Pharmacy & Pharmaceutical Sciences, M.S. in oncology University of New York at Buffalo, B.S. in biology and Pre-Med, Canisius College.
Positions
- Company NameMediciNova, Inc.Stock CodeMNOVPositionChief Business Officer
